BANAN (cefpodoxime proxetil) by Daiichi Sankyo is clinical pharmacology absorption and excretion: cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Approved for development of drug-resistant bacteria, maintain the effectiveness of cefpodoxime proxetil, other antibacterial drugs and 3 more indications. First approved in 1992.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
BANAN (cefpodoxime proxetil) is an oral third-generation cephalosporin antibiotic approved in 1992 for treating bacterial infections caused by susceptible pathogens. It is a prodrug absorbed from the GI tract and de-esterified to its active metabolite cefpodoxime, which inhibits bacterial cell wall synthesis. The drug achieves adequate tissue penetration, including in skin, tonsillar, and other tissues, with 50% bioavailability and minimal hepatic metabolism.
Product approaching loss of exclusivity with minimal recent spending data, suggesting reduced commercial investment and smaller brand support teams.
CLINICAL PHARMACOLOGY Absorption and Excretion: Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the…
Worked on BANAN at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients.
Coolsculpting With Cooltone Verses Coolsculpting Alone for the Banana Roll Area
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
Working on BANAN offers limited career acceleration; the product is approaching loss of exclusivity with no linked job openings and declining commercial investment. Career value lies in managing mature portfolio decline, cost optimization, and potentially transitioning to growth-stage assets within the sponsor's pipeline.